Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced the presentation of preclinical data supporting its lead investigational therapy, C-1101, at the Orthopaedic Research Society (ORS) 2026 Annual Meeting in Charlotte, NC. The data were presented in...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida....
Consano Bio today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101 into clinical development for chronic lumbosacral radiculopathy (LSR), or chronic sciatica....
Consano Bio today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College...